Puma Biotechnology
PBYI
154 hedge funds and large institutions have $3.1B invested in Puma Biotechnology in 2017 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 48 increasing their positions, 48 reducing their positions, and 26 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 2 → 6 (+4)
120% more capital invested
Capital invested by funds: $1.41B → $3.1B (+$1.69B)
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
13% more funds holding
Funds holding: 136 → 154 (+18)
3% more call options, than puts
Call options by funds: $130M | Put options by funds: $125M
0% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 48
6.65% less ownership
Funds ownership: 102.74% → 96.09% (-6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$128M |
| 2 |
Janus Henderson Group
London,
|
+$104M |
| 3 |
PA
Perceptive Advisors
New York
|
+$41M |
| 4 |
Millennium Management
New York
|
+$36.4M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$34.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$131M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$57.1M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$48.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$46.6M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$24.2M |
PBYI Hedge Fund Activity: Q2 2017 in Review
154 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q2 2017, worth a combined $3.1B — up 120% from $1.41B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PBYI positions and 26 closed out — a net gain of 19 holders — while 48 added to existing stakes and 48 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $128M. The largest seller was Adage Capital Partners, cutting an estimated $131M.
- 154 institutional investors held Puma Biotechnology (PBYI) as of Q2 2017, up from 136 in Q1 2017.
- Funds reported $3.1B of Puma Biotechnology stock for Q2 2017, up 120% quarter-over-quarter.
- 45 funds opened new Puma Biotechnology positions in Q2 2017 and 26 closed out, a net change of +19 holders.
- The largest Puma Biotechnology buyer in Q2 2017 was T. Rowe Price Associates, an estimated $128M added.
- The largest Puma Biotechnology seller in Q2 2017 was Adage Capital Partners, an estimated $131M sold.
Based on aggregated 13F filings for Q2 2017.